Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, Hicheri Y, Wartiovaara-Kautto U, Raffoux E, Cluzeau T, Balsat M, Roth-Guepin G, Tavernier E, Lepretre S, Bilger K, Bergugnat H, Berceanu A, Alexis M, Doubek M, Brissot E, Hunault-Berger M, Lebon D, Turlure P, Chantepie S, Belhabri A, Wickenhauser S, Bastie JN, Cacheux V, Himberlin C, Banos A, Gardin C, Bonnet S, Plantier I, Pica GM, Escoffre-Barbe M, Boissel N, Dombret H, Clappier E, Rousselot P; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) and the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL). Chevallier P, et al. Among authors: balsat m. J Clin Oncol. 2024 Dec 20;42(36):4327-4341. doi: 10.1200/JCO.24.00490. Epub 2024 Oct 17. J Clin Oncol. 2024. PMID: 39418626 Clinical Trial.
Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry.
Rabian F, Beauvais D, Marchand T, Fürst S, Huynh A, Brissot E, Maury S, Gabellier L, Chevallier P, Loschi M, Nguyen S, Balsat M, Lafon I, Fayard A, Camus V, Simand C, Moya N, Castilla-Llorente C, Joris M, Berceanu A, Thiebaut-Bertrand A, Lhéritier V, Gehlkopf E, Roth-Guépin G, Leguay T, Boissel N. Rabian F, et al. Among authors: balsat m. Blood Adv. 2024 Nov 12;8(21):5493-5496. doi: 10.1182/bloodadvances.2024013962. Blood Adv. 2024. PMID: 39207868 Free PMC article. No abstract available.
Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT.
Giebel S, Labopin M, Peric Z, Passweg J, Blaise D, Salmenniemi U, Beauvais D, Reményi P, Chevallier P, Mielke S, Gedde-Dahl T, Cornelissen JJ, Balsat M, Bug G, Bazarbachi A, Brissot E, Nagler A, Ciceri F, Mohty M. Giebel S, et al. Among authors: balsat m. Transplant Cell Ther. 2025 Jan;31(1):14.e1-14.e10. doi: 10.1016/j.jtct.2024.07.016. Epub 2024 Jul 26. Transplant Cell Ther. 2025. PMID: 39069077
Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.
Kim R, Chalandon Y, Rousselot P, Cayuela JM, Huguet F, Balsat M, Passet M, Chevallier P, Hicheri Y, Raffoux E, Leguay T, Chantepie S, Maury S, Hayette S, Solly F, Braun T, De Prijck B, Cacheux V, Salanoubat C, Farnault L, Guibaud I, Lamarque M, Gastaud L, Lemasle E, Brissot E, Tavernier E, Bilger K, Villate A, Soulier J, Graux C, Lhéritier V, Dombret H, Boissel N, Clappier E. Kim R, et al. Among authors: balsat m. J Clin Oncol. 2024 Sep 10;42(26):3140-3150. doi: 10.1200/JCO.24.00108. Epub 2024 Jul 19. J Clin Oncol. 2024. PMID: 39028928
NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.
Simonin M, Vasseur L, Lengliné E, Lhermitte L, Cabannes-Hamy A, Balsat M, Schmidt A, Dourthe ME, Touzart A, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Huguet F, Ducassou S, Lhéritier V, Chalandon Y, Ifrah N, Dombret H, Macintyre E, Petit A, Rousselot P, Lambert J, Baruchel A, Boissel N, Asnafi V. Simonin M, et al. Among authors: balsat m. Blood. 2024 Oct 10;144(15):1570-1580. doi: 10.1182/blood.2023023754. Blood. 2024. PMID: 38848537
Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party.
El Cheikh J, Ngoya M, Galimard JE, Reményi P, Kulagin A, Aljurf M, Mousavi A, Wu D, Ozcelik T, Salmenniemi U, Castilla-Llorente C, Socie G, Helbig G, Schroeder T, Sakellari I, Rambaldi A, Burt R, Busca A, Balsat M, Stelljes M, Brissot E, Giebel S, Peric Z, Nagler A, Bazarbachi A, Ciceri F, Mohty M. El Cheikh J, et al. Among authors: balsat m. Bone Marrow Transplant. 2024 Sep;59(9):1239-1246. doi: 10.1038/s41409-024-02300-8. Epub 2024 Jun 4. Bone Marrow Transplant. 2024. PMID: 38834689
Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL.
Balducci E, Simonin M, Duployez N, Steimlé T, Dourthe ME, Villarese P, Ducassou S, Arnoux I, Cayuela JM, Balsat M, Courtois L, Andrieu G, Touzart A, Huguet F, Petit A, Ifrah N, Dombret H, Baruchel A, Macintyre E, Preudhomme C, Boissel N, Asnafi V. Balducci E, et al. Among authors: balsat m. Blood. 2024 Aug 29;144(9):988-1000. doi: 10.1182/blood.2023022154. Blood. 2024. PMID: 38518104 Clinical Trial.
PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
Pinton A, Courtois L, Doublet C, Cabannes-Hamy A, Andrieu G, Smith C, Balducci E, Cieslak A, Touzart A, Simonin M, Lhéritier V, Huguet F, Balsat M, Dombret H, Rousselot P, Spicuglia S, Macintyre E, Boissel N, Asnafi V. Pinton A, et al. Among authors: balsat m. Clin Cancer Res. 2024 Jan 5;30(1):94-105. doi: 10.1158/1078-0432.CCR-23-2159. Clin Cancer Res. 2024. PMID: 37889114
57 results